Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ZLAB with free AI briefings, catalyst countdowns, and dilution alerts.

ZLAB · Zai Lab Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$559.7M Cash on Hand
27.7mo Cash Runway
Follow ZLAB by email Get an email when ZLAB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZLAB, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2026-11-30 Povetacicept (Vertex) immunoglobulin A nephropathy (IgAN) BLA 64%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What ZLAB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Povetacicept Primary Membranous Nephropathy Phase 2/3 · NCT07204275 Recruiting
Moxifloxacin Community-acquired Bacterial Pneumonia Phase 3 · NCT06162286 Unknown
Tebotelimab (MGD013) Gastric Cancer Phase 2/3 · NCT04082364 Completed
mFOLFOX6 Gastric Cancer Phase 3 · NCT05052801 Completed
Investigator's Choice of Therapy Small-cell Lung Cancer Phase 3 · NCT07218146 Recruiting
ZL-1109 (VRDN-003) Thyroid Eye Disease (TED) Phase 3 · NCT07211776 Active not recruiting
Zocilurtatug Pelitecan (ZL-1310) Small-cell Lung Cancer Phase 3 · NCT07218146 Recruiting
ZL-2306 (Nirapairb) Ovarian Cancer Phase 3 · NCT03709316 Unknown
Bemarituzumab Gastric Cancer Phase 3 · NCT05052801 Completed
Sunitinib Gastrointestinal Stromal Tumor(GIST) Phase 2 · NCT04633122 Completed
ZL-1102 1% w/w gel BID for 16 weeks Plaque Psoriasis Phase 2 · NCT06380907 Terminated
ZL-1102 3% w/w gel BID for 16 weeks Plaque Psoriasis Phase 2 · NCT06380907 Terminated
ZL-1102 3% w/w gel QD for 16 weeks Plaque Psoriasis Phase 2 · NCT06380907 Terminated
ZL-3101 Eczema Phase 2 · NCT03134352 Completed
Obrixtamig Small Cell Lung Cancer Phase 1/2 · NCT07707895 Recruiting
Catequentinib Platinum-resistant Recurrent Clear Cell Ovarian Cancer Phase 2 · NCT05130515 Completed

Also used in these trials (approved or third-party drugs, not ZLAB's own candidates): Capecitabine, Oxaliplatin, Retifanlimab, Tacrolimus Extended-Release, Trastuzumab, Xanomeline And Trospium Chloride, Margetuximab, Repotrectinib, Crizotinib, Omadacycline, Atezolizumab, Niraparib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ZLAB holds $559.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $60.6M/quarter from operations, an estimated runway of 27.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 29 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZLAB files for a raise →

👥 Who Owns ZLAB

Insiders 2.8% Other 5%+ holders 66.7% Institutions 30.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
RTW Investments, LP Institution (13G, 5%+) 69,590,320 78.55% 2025-12-31
Chen Yu 5%+ holder (13G) 59,130,750 66.74% 2026-06-02
RA Capital Management, L.P. Institution (13G, 5%+) 57,435,330 64.83% 2026-03-30
Ying Du
Chairperson & CEO, Director · +105,972 options
Insider 1,221,401 1.38% 2026-07-01
Peter Wirth
Director
Insider 416,121 0.47% 2026-06-17
John D Diekman
Director
Insider 122,140 0.14% 2026-06-17
Joshua L Smiley
President and Chief Operating Officer · +128,982 options
Insider 117,602 0.13% 2026-04-06
Nisa Leung
Director
Insider 96,297 0.11% 2026-06-17
Leon O Jr Moulder
Director
Insider 94,973 0.11% 2026-06-17
Richard Gaynor
Director
Insider 81,965 0.09% 2026-11-10
Michel Vounatsos
Director
Insider 72,787 0.08% 2026-06-17
Rafael Amado
President, Head of Global Oncology Resea · +20,296 options
Insider 57,022 0.06% 2026-04-06

Share count 88,592,343 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ZLAB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZLAB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.